Publications by authors named "Gemma Moreno Jimenez"
Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively.
View Article and Find Full Text PDFSurvival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.
Front Oncol
May 2024
Article Synopsis
- Pretransplant measurement of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT) impacts their prognosis, particularly in relation to conditioning intensity.
- * The study analyzed transplant outcomes of 118 AML patients, revealing that those with positive MRD (MRD+) before HSCT had significantly worse event-free survival (EFS) and higher relapse rates compared to those with negative MRD (MRD-).
- * Among patients treated with myeloablative conditioning (MAC), MRD- patients fared better in terms of EFS and overall survival, while those receiving reduced intensity conditioning (RIC) showed similar outcomes, regardless of MRD status.*
Caplacizumab prevents the interaction between von Willebrand factor and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes, 75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura.
View Article and Find Full Text PDFPatients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Hematol Oncol
October 2023
Article Synopsis
- Patients with secondary acute myeloid leukemia (s-AML) do not do as well after treatment compared to those with regular (de novo) acute myeloid leukemia (AML).
- A study compared 58 s-AML patients with 52 de novo AML patients who had a stem-cell transplant.
- The results showed that s-AML patients had a higher chance of health problems and dying after the transplant, especially if they weren’t in complete remission before the procedure.
Article Synopsis
- Autologous hematopoietic stem cell transplantation (ASCT) can improve survival rates in multiple myeloma (MM), but some patients struggle to collect enough HSPCs using standard methods like G-CSF.
- The GENESIS trial tested a new drug, motixafortide, combined with G-CSF, against a placebo and G-CSF to see if it could help mobilize more HSPCs for ASCT.
- Results showed that motixafortide significantly increased the number of patients who collected sufficient HSPCs, outperforming the placebo group, and its side effects were generally mild and manageable.
Background And Objectives: Calculation of blood volume (BV) to be processed to achieve the target number of CD34+ cells can be accomplished by using collection efficiency 2 (CE2) formula. Our aim was to develop a BV web formula.
Materials And Methods: We calculated CE2 from aphereses performed between January 2015 and March 2020 in allogeneic donors and patients.
Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab.
View Article and Find Full Text PDFArticle Synopsis
- Plerixafor (Mozobil) is approved for patients with lymphoma and multiple myeloma when traditional mobilization methods fail, and its off-label use in healthy related donors (HRDs) lacks comprehensive data and guidelines.
- An observational study involving 30 HRDs in Spain found that administering plerixafor after G-CSF mobilization failure significantly increased the collection of CD34+ cells.
- While mild side effects were reported in about 27% of donors, the addition of plerixafor resulted in a higher median total of CD34+ cells collected compared to using G-CSF alone.
Background: During the COVID-19 outbreak, most hospitals deferred elective surgical procedures to allow space for the overwhelming number of COVID-19 patient admissions, expecting a decrease in routine blood component requirements. However, because transfusion support needs of COVID-19 patients are not well known, its impact on hospital blood supply is uncertain. The objective of this study was to assess the effect of the COVID-19 pandemic on transfusion demand.
View Article and Find Full Text PDF